Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

This study is testing a three-drug combination — zanubrutinib (a targeted oral drug), rituximab (an antibody), and venetoclax (another targeted oral drug) — as a first-line treatment for people newly diagnosed with follicular lymphoma, a slow-growing type of blood cancer. **You may be eligible if...** - You have newly diagnosed follicular lymphoma (grades 1, 2, or 3a) that has not been treated - You have stage II, III, or IV disease - You have symptoms requiring treatment, such as fever, night sweats, significant weight loss, fatigue, enlarged spleen, or low blood counts - You have at least one measurable lesion **You may NOT be eligible if...** - You have already received treatment for follicular lymphoma - Your lymphoma does not yet require treatment (no symptoms, no organ compression) - You have serious organ problems or blood count abnormalities beyond what lymphoma causes - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.